Nimotuzumab (h-R3, BIOMAb EGFR, Biocon, India; TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology...
8 KB (811 words) - 23:38, 22 May 2024
India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus)...
30 KB (2,613 words) - 18:01, 2 July 2024
YM Biosciences (section Nimotuzumab research)
The company also advanced other clinical-stage products, including Nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a vascular disrupting...
5 KB (515 words) - 02:23, 24 January 2021
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
149 KB (15,717 words) - 11:43, 7 August 2024
HER2/neu overexpression targets the HER2/neu (erbB2) receptor humanized nimotuzumab approved in squamous cell carcinomas, Glioma clinical trials for other...
49 KB (4,964 words) - 04:02, 9 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
31 KB (3,428 words) - 11:40, 29 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
121 KB (13,799 words) - 03:46, 30 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
93 KB (8,776 words) - 07:12, 1 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
13 KB (1,177 words) - 16:45, 16 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
68 KB (5,999 words) - 09:02, 6 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
25 KB (2,086 words) - 02:24, 16 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
42 KB (3,935 words) - 04:01, 30 April 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
16 KB (1,784 words) - 04:08, 6 January 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
10 KB (579 words) - 06:46, 26 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
5 KB (412 words) - 23:17, 19 June 2023
(Russia) plaque psoriasis, psoriatic arthritis, ankylosing spondylitis Nimotuzumab BioMab-EGFR, Theracim, Theraloc mab humanized epidermal growth factor...
135 KB (4,054 words) - 22:35, 2 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
20 KB (1,543 words) - 06:38, 10 March 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
34 KB (3,021 words) - 12:39, 5 August 2024
nimetazepam (INN) nimidane (INN) nimodipine (INN) nimorazole (INN) Nimotop nimotuzumab (INN) nimustine (INN) niometacin (INN) Nipent Nipent (Parke-Davis Pharmaceutical...
9 KB (421 words) - 04:33, 2 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
27 KB (3,071 words) - 04:54, 3 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
10 KB (661 words) - 04:10, 26 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
24 KB (2,877 words) - 10:08, 2 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
24 KB (1,700 words) - 04:21, 2 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
46 KB (5,344 words) - 04:27, 29 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
64 KB (7,427 words) - 21:08, 3 August 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
21 KB (1,649 words) - 23:02, 17 April 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
110 KB (10,711 words) - 05:46, 12 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
11 KB (934 words) - 20:16, 26 July 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
22 KB (1,994 words) - 04:41, 3 January 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:...
17 KB (1,708 words) - 13:56, 21 July 2024